Atherosclerotic Cardiovascular Disease Clinical Trials in Paris
5 recruitingParis, France
Showing 1–5 of 5 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Not Applicable
Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)
Atherosclerotic Cardiovascular Disease (ASCVD)Familial Hypercholesterolemias
Nantes University Hospital600 enrolled9 locationsNCT06960902